Patents by Inventor Stephen W. Queener

Stephen W. Queener has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6322998
    Abstract: The present invention provides DNA compounds that encode ACV synthetase activity of Cephalosporium acremonium. The compounds can be used to construct recombinant DNA expression vectors for a wide variety of host cells, including E. coli, Penicillium, Cephalosporium, and Aspergillus.
    Type: Grant
    Filed: October 29, 1992
    Date of Patent: November 27, 2001
    Assignee: Eli Lilly and Company
    Inventors: Cathleen A. Cantwell, Roland L. Hodges, JoAnn Hoskins, Stephen W. Queener, Paul L. Skatrud
  • Patent number: 6180361
    Abstract: The present invention provides DNA compounds that encode the expandase/hydroxylase enzyme of Cephalosporium acremonium. The compounds can be used to construct recombinant DNA expression vectors for a variety of host cells, including E. coli, Penicillium, and Cephalosporium.
    Type: Grant
    Filed: December 12, 1988
    Date of Patent: January 30, 2001
    Assignee: Eli Lilly and Company
    Inventors: Thomas D. Ingolia, Stephen W. Queener, Suellen M. Samson, Paul L. Skatrud
  • Patent number: 5658755
    Abstract: Heterologous extra-cellular expression of recombinant proteins in soluble functional form is desirable because of the ease associated with purification of the secreted proteins and avoidance of the need for cell extraction and protein refolding procedures. The present invention provides DNA sequences of the naturally-occurring phthalyl amidase gene isolated from Xanthobacter agilis that control transcription, translation, and extra-cellular secretion of proteins in Streptomyces lividans. These DNA sequences can be used in a method for extra-cellular expression of a wide variety of proteins in soluble functional form.
    Type: Grant
    Filed: July 15, 1994
    Date of Patent: August 19, 1997
    Assignee: Eli Lilly and Company
    Inventors: Stephen W. Queener, Joseph M. Zock
  • Patent number: 5543497
    Abstract: Phthalyl amidase is an enzyme previously unknown in the art that catalyzes removal of the phthalyl moiety from phthalyl-containing amides. The current invention provides DNA compounds encoding the phthalyl amidase enzyme and methods for expressing such compounds. The present invention also provides recombinant DNA vectors encoding phthalyl amidase and host cells transformed with these DNA vectors.
    Type: Grant
    Filed: May 22, 1995
    Date of Patent: August 6, 1996
    Assignee: Eli Lilly and Company
    Inventors: Stephen W. Queener, Joseph M. Zock
  • Patent number: 5468632
    Abstract: The present invention provides isolated DNA compounds and recombinant DNA cloning and expression vectors that encode PNB esterase from Bacillus subtilis. The invention also provides host cells transformed with these vectors and a method for production of the PNB esterase by recombinant DNA techniques.
    Type: Grant
    Filed: September 22, 1993
    Date of Patent: November 21, 1995
    Assignee: Eli Lilly and Company
    Inventors: Cathleen A. Cantwell, Roland L. Hodges, Derek McGilvray, Stephen W. Queener, James R. Swartling, Joseph M. Zock
  • Patent number: 5451522
    Abstract: Phthalyl amidase is an enzyme previously unknown in the art that catalyzes removal of the phthalyl moiety from phthalyl-containing amides. The current invention provides DNA compounds encoding the phthalyl amidase enzyme and methods for expressing such compounds. The present invention also provides recombinant DNA vectors encoding phthalyl amidase and host cells transformed with these DNA vectors.
    Type: Grant
    Filed: July 15, 1994
    Date of Patent: September 19, 1995
    Assignee: Eli Lilly and Company
    Inventors: Stephen W. Queener, Joseph M. Zock
  • Patent number: 4892819
    Abstract: The present invention comprises novel DNA compounds that encode isopenicillin N synthetase. The invention also comprises methods, transformants, and polypeptides related to the novel DNA compounds. The novel isopenicillin N synthetase-encoding DNA, together with its associated transcription and translation activating sequence, was isolated from Penicillium chrysogenum. The isopenicillin N synthetase-encoding DNA can be used to construct novel E. coli expression vectors that drive expression of isopenicillin N synthetase in E. coli. The intact P. chrysogenum isopenicillin N synthetase-encoding DNA and associated transcription and translation activating sequence can also be used to construct expression vectors that drive expression of the isopenicillin N synthetase in P. chrysogenum and Cephalosporium acremonium. The transcription and translation activating sequence can be fused to a hygromycin phosphotransferase-encoding DNA segment and placed onto expression vectors that function in P. chrysogenum and C.
    Type: Grant
    Filed: November 25, 1985
    Date of Patent: January 9, 1990
    Assignee: Eli Lilly and Company
    Inventors: Lucinda G. Carr, Thomas D. Ingolia, Stephen W. Queener, Paul L. Skatrud
  • Patent number: 4885251
    Abstract: The present invention comprises novel DNA compounds that encode isopenicillin N synthetase and also comprises related methods, transformants, and polypeptides. The novel isopenicillin N synthetase-encoding DNA, together with its associated transcriptional and translational activating sequence, was isolated from Cephalosporium acremonium and cloned into an E. coli cloning vector. The isopenicillin N synthetase-encoding DNA has been used to construct novel E. coli expression vectors that drive expression of a stable, active, and novel isopenicillin N synthetase in E. coli. The intact C. acremonium isopenicillin N synthetase-encoding DNA and associated transcriptional and translational activating sequence have also been used to construct C. acremonium expression vectors that drive expression of the isopenicillin N synthetase in C. acremonium. The C. acremonium transcriptional and translational activating sequence has further been fused to a hygromycin phosphotransferase-encoding DNA segment and placed onto C.
    Type: Grant
    Filed: August 8, 1986
    Date of Patent: December 5, 1989
    Assignee: Eli Lilly and Company
    Inventors: Thomas D. Ingolia, Stephen W. Queener, Suellen M. Samson, Paul L. Skatrud, Otis W. Godfrey
  • Patent number: 4885252
    Abstract: DNA compounds and recombinant DNA expression vectors that encode and drive expression in recombinant host cells of the isopenicillin N synthetase activity of Aspergillus nidulans are useful to produce isopenicillin N synthetase and to improve the yield of .beta.-lactam-containing antibiotics from antibiotic-producing organisms. The isopenicillin N synthetase gene of A. nidulans can be isolated from plasmid pOGOO4, available from the Northern Regional Research Center under the accession number NRRL B-18171.
    Type: Grant
    Filed: December 14, 1987
    Date of Patent: December 5, 1989
    Assignee: Eli Lilly and Company
    Inventors: Thomas D. Ingolia, Stephen W. Queener, Paul L. Skatrud, Barbara J. Wiegel
  • Patent number: 4762786
    Abstract: A method for transforming Cephalosporium and other lower eukaryotes is disclosed. The method involves inserting a recombinant DNA cloning vector comprising a Saccharomyces cerevisiae transcriptional and translational activating sequence positioned for expression of hygromycin phosphotransferase into a host cell and then growing the host cell under selective conditions. The vectors optionally further comprise Cephalosporium ribosomal DNA and also sequences that allow for replication and selection in E. coli and Streptomyces.
    Type: Grant
    Filed: September 27, 1984
    Date of Patent: August 9, 1988
    Assignee: Eli Lilly and Company
    Inventors: Jerry L. Chapman, Jr., Thomas D. Ingolia, Kevin R. Kaster, Stephen W. Queener, Paul L. Skatrud
  • Patent number: 4115197
    Abstract: A procedure for efficiently obtaining higher mycophenolic-acid-producing mutants from mycophenolic-acid-producing strains of the genus Penicillium by selecting mutants which are resistant to polyene antibiotics.
    Type: Grant
    Filed: August 29, 1977
    Date of Patent: September 19, 1978
    Assignee: Eli Lilly and Company
    Inventors: Stephen W. Queener, Claude H. Nash, III